Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis

doi:10.4254/wjh.v7.i22.2404

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 22

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11450)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

568

WORD

231

HTML

4506

Tables (1-3)

598

Sum=5903

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

620

Download

1503

Sum=2123

Publishing Process of This Article

Item

Count

Browse

1332

Download

2092

Sum=3424

Oct 8, 2015 (publication date) through Mar 5, 2026

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Hepatol. Oct 8, 2015; 7(22): 2404-2410
Published online Oct 8, 2015. doi: 10.4254/wjh.v7.i22.2404

Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis

Koichi Honda, Masataka Seike, Kazunari Murakami

Koichi Honda, Masataka Seike, Kazunari Murakami, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu-City, Oita 879-5593, Japan

Author contributions: Honda K, Seike M and Murakami K designed the review aricle; Honda K wrote the manuscript; Seike M and Murakami K revised the manuscript.

Conflict-of-interest statement: We declare that we have no conflict of interest.

Correspondence to: Koichi Honda, MD, PhD, Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita 879-5593, Japan. hondak@oita-u.ac.jp

Telephone: +81-97-5866193 Fax: +81-97-5866194

Received: April 27, 2015
Peer-review started: May 4, 2015
First decision: July 17, 2015
Revised: August 2, 2015
Accepted: September 7, 2015
Article in press: September 8, 2015
Published online: October 8, 2015
Processing time: 157 Days and 20.5 Hours

Core Tip

Core tip: We presented the benefits of nucleos(t)ide analogs (NUCs) treatments for HBV-related cirrhosis in this article. NUC treatments have been found to improve inflammation and fibrosis in the liver of cirrhotic patients. Moreover, even in patients with decompensated cirrhosis, liver function has improved in many cases. Furthermore, although NUC treatments can reduce the incidence of hepatocellular carcinoma (HCC), rates of HCC remain high in patients with cirrhosis. NUC treatments have been found to improve liver function and the survival of patients with HCC. Improved liver function was also achieved by providing NUC treatments for hepatitis B virus-related HCC when recurrent tumors developed. Therefore, it is important to select the most appropriate treatment method considering the alterations in liver function that may occur following NUC treatments.